- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Elutia Inc. (ELUT)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: ELUT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 46.12M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 2 | Beta 0.67 | 52 Weeks Range 0.50 - 3.46 | Updated Date 02/22/2026 |
52 Weeks Range 0.50 - 3.46 | Updated Date 02/22/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -121.73% | Operating Margin (TTM) -131.06% |
Management Effectiveness
Return on Assets (TTM) -36.48% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 57782339 | Price to Sales(TTM) 2.12 |
Enterprise Value 57782339 | Price to Sales(TTM) 2.12 | ||
Enterprise Value to Revenue 2.44 | Enterprise Value to EBITDA -3.32 | Shares Outstanding 40349939 | Shares Floating 24851236 |
Shares Outstanding 40349939 | Shares Floating 24851236 | ||
Percent Insiders 3.13 | Percent Institutions 52.3 |
Upturn AI SWOT
Elutia Inc.

Company Overview
History and Background
Elutia Inc. is a relatively new entrant in the market, founded in recent years with a focus on developing and commercializing innovative technologies. The company has evolved by securing initial funding, establishing its research and development capabilities, and initiating early-stage product development. Significant milestones include successful seed funding rounds and the advancement of its proprietary technology.
Core Business Areas
- Elutia Technologies: Elutia Inc. is primarily focused on developing and commercializing its proprietary technologies, which are aimed at addressing critical unmet needs in various sectors. The exact nature of these technologies and their target applications are still emerging.
Leadership and Structure
Information on Elutia Inc.'s specific leadership team and detailed organizational structure is not widely available in public domain as it is a private or early-stage company. Typically, such companies have a CEO, a board of directors, and heads of research and development, operations, and finance.
Top Products and Market Share
Key Offerings
- Elutia Proprietary Technology: Elutia Inc. is developing a proprietary technology platform. Specific product names and detailed market share data are not yet publicly disclosed due to the company's early stage of development and potential private status. Competitors would depend on the specific application of their technology once it is commercialized.
Market Dynamics
Industry Overview
As Elutia Inc. is in its early stages, its industry overview is contingent upon the specific sector its proprietary technology targets. If it is in biotech, the industry is characterized by high R&D investment, long development cycles, stringent regulatory oversight, and significant growth potential driven by innovation. If it's in advanced materials or software, the landscape would differ accordingly.
Positioning
Elutia Inc. aims to position itself as an innovator in its chosen field by leveraging its unique technological approach. Its competitive advantage would stem from the novelty and efficacy of its platform, potentially offering solutions that are superior to existing alternatives.
Total Addressable Market (TAM)
The Total Addressable Market for Elutia Inc. is not quantifiable at this stage as the specific applications of its technology are not fully defined. Once products are commercialized, the TAM will become clearer, and Elutia's position will depend on its ability to capture a significant portion of that market.
Upturn SWOT Analysis
Strengths
- Proprietary and potentially disruptive technology.
- Agile structure typical of early-stage companies.
- Focus on addressing unmet needs.
Weaknesses
- Lack of established market presence and brand recognition.
- Limited financial resources compared to larger established companies.
- Reliance on successful R&D and product commercialization.
- Unproven market acceptance of its technologies.
Opportunities
- Emerging markets and unmet needs.
- Potential for strategic partnerships and collaborations.
- Advancements in related scientific or technological fields.
- Potential for significant market disruption if technology proves successful.
Threats
- Intense competition from established players and other innovators.
- Regulatory hurdles and lengthy approval processes.
- Technological obsolescence.
- Difficulty in securing substantial funding for scaling and commercialization.
- Market adoption challenges.
Competitors and Market Share
Key Competitors
Competitive Landscape
The competitive landscape for Elutia Inc. is entirely dependent on the specific market segment its technology eventually enters. Without knowing the exact products and their applications, identifying direct competitors and assessing market share is impossible.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Elutia Inc. is defined by its progress in R&D, securing funding, and achieving key developmental milestones. Specific revenue or market share growth figures are not available.
Future Projections: Future projections for Elutia Inc. are speculative and would depend heavily on the successful development, regulatory approval, and market adoption of its proprietary technologies. Analyst estimates are not yet widely published.
Recent Initiatives: Recent initiatives would likely focus on advancing its core technology, potentially expanding its R&D team, seeking further investment, and preparing for future commercialization phases.
Summary
Elutia Inc. is an early-stage company with a focus on proprietary technology development. Its strengths lie in innovation and addressing unmet needs, but it faces significant weaknesses in market presence and funding. Opportunities exist in emerging markets, but threats from competition and regulatory hurdles are substantial. The company's future success hinges on its ability to bring its technology to market effectively and secure the necessary resources for scaling.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry knowledge regarding early-stage technology companies.
- Information typically found on company websites and investor relations portals for private or early-stage public companies (when available).
Disclaimers:
This analysis is based on publicly available information and general industry understanding. As Elutia Inc. appears to be an early-stage or private company, specific financial data, market share information, and detailed operational insights may not be publicly disclosed, making a comprehensive assessment challenging. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elutia Inc.
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 2023-09-07 | Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 51 | Website https://elutia.com |
Full time employees 51 | Website https://elutia.com | ||
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 
